| 摘要 |
<p>The present invention relates to a methylated marker which is specialized in a bile duct carcinoma and to uses thereof by determining the methylated state of one or more genes which are selected from a group which is composed of TWIST1, HOXA1, SFRP1, PENK, GRIN2B, CDH13, NEUROG1, TIMP3, MINT2, CCND2, RASSF1A, RUNX3, CRABP1, GATA3, SEZ6L, SOCS3, and BCL2 in a biological sample. The methylated marker gene according to the present invention supplements a low sensitivity which a biliary cell pathology has and remarkably improves a diagnosis rate before a surgery of a bile duct carcinoma since the bile duct carcinoma can be easily diagnosed with high sensitivity and high specificity in advance by using bile.</p> |
